Insider Selling: Illumina (NASDAQ:ILMN) CAO Sells $225,150.00 in Stock

Illumina, Inc. (NASDAQ:ILMN) CAO Scott Ericksen sold 1,500 shares of the business’s stock in a transaction on Thursday, May 28th. The stock was sold at an average price of $150.10, for a total transaction of $225,150.00. Following the transaction, the chief accounting officer directly owned 14,946 shares in the company, valued at approximately $2,243,394.60. The trade was a 9.12% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Illumina Trading Up 5.2%

NASDAQ ILMN opened at $170.93 on Thursday. The company has a current ratio of 1.75, a quick ratio of 1.36 and a debt-to-equity ratio of 0.56. The company’s fifty day simple moving average is $136.19 and its 200-day simple moving average is $133.03. The stock has a market cap of $25.86 billion, a P/E ratio of 31.08, a PEG ratio of 2.69 and a beta of 1.50. Illumina, Inc. has a 52 week low of $81.75 and a 52 week high of $172.49.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings results on Thursday, April 30th. The life sciences company reported $1.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.05 by $0.10. The business had revenue of $1.09 billion during the quarter, compared to analyst estimates of $1.07 billion. Illumina had a net margin of 19.42% and a return on equity of 31.01%. The business’s revenue was up 4.8% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.97 earnings per share. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. Equities research analysts predict that Illumina, Inc. will post 5.2 EPS for the current fiscal year.

Institutional Trading of Illumina

Several institutional investors have recently added to or reduced their stakes in ILMN. MassMutual Private Wealth & Trust FSB increased its holdings in Illumina by 7.9% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 1,081 shares of the life sciences company’s stock worth $142,000 after buying an additional 79 shares during the last quarter. HighPoint Advisor Group LLC increased its holdings in Illumina by 3.7% in the fourth quarter. HighPoint Advisor Group LLC now owns 2,218 shares of the life sciences company’s stock worth $291,000 after buying an additional 80 shares during the last quarter. Meeder Advisory Services Inc. increased its holdings in Illumina by 3.1% in the first quarter. Meeder Advisory Services Inc. now owns 2,822 shares of the life sciences company’s stock worth $348,000 after buying an additional 85 shares during the last quarter. Toronto Dominion Bank increased its holdings in Illumina by 0.3% in the fourth quarter. Toronto Dominion Bank now owns 33,605 shares of the life sciences company’s stock worth $4,407,000 after buying an additional 92 shares during the last quarter. Finally, Assetmark Inc. increased its holdings in Illumina by 10.2% in the third quarter. Assetmark Inc. now owns 1,039 shares of the life sciences company’s stock worth $99,000 after buying an additional 96 shares during the last quarter. Institutional investors own 89.42% of the company’s stock.

Analyst Ratings Changes

A number of analysts recently issued reports on the stock. Piper Sandler dropped their price target on shares of Illumina from $195.00 to $170.00 and set an “overweight” rating for the company in a research note on Monday, February 9th. Evercore restated an “outperform” rating on shares of Illumina in a research note on Friday, May 1st. Robert W. Baird set a $137.00 price target on shares of Illumina in a research note on Friday, February 6th. Guggenheim lifted their price target on shares of Illumina from $170.00 to $180.00 and gave the stock a “buy” rating in a research note on Monday. Finally, Barclays lifted their price target on shares of Illumina from $110.00 to $122.00 and gave the stock an “underweight” rating in a research note on Friday, May 1st. Seven research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $138.38.

More Illumina News

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Guggenheim raised its price target on Illumina to $180 from $170 and reiterated a Buy rating, reflecting optimism about clinical sequencing momentum, consumables pricing, and the company’s pipeline. Article
• Positive Sentiment: Integrated DNA Technologies expanded its collaboration with Illumina, linking xGen FFPE and cfDNA workflows to DRAGEN and Connected Insights, which could deepen Illumina’s role in oncology research and support software adoption. Article
• Positive Sentiment: Recent commentary highlighted Illumina’s better execution, stronger NovaSeq X adoption, and higher full-year 2026 guidance, which has helped extend the stock’s rally. Article
• Neutral Sentiment: Illumina reported small insider sales, including a routine Rule 10b5-1 sale by the chief accounting officer, which is not unusual but adds to scrutiny around insider activity. SEC filing
• Negative Sentiment: Director Keith A. Meister sold a large block of shares in multiple transactions, which could weigh on sentiment despite no direct sign of operational weakness. SEC filing

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.